Diabetes Complications Flashcards

1
Q

Mechanisms of hyperglycemia ==> micro-vascular diabetic complications

A
  • polyol pathway
  • non-enzyme glycosylation ==> pro-inflammatory pathway
  • elevation of protein kinase C (PKC)
  • oxidative carbonyl stress
  • Bownlee unifying hypothesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Characteristics of polyol pathway in DM

A
  • Glucose → sorbitol / fructose → osmotic + oxidative stress → abnormal cellular function
  • Aldose reductase is the therapeutic target
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Characteristics of non-enzymatic glycosylation pathway in DM

A
  • hyperglycemia ==> more glucose bind to amines and nucleic acids ==> irreversible rxns ==> advanced glycosylation end products (AGE)
  • AGEs ==> diabetic complications: nephropathy, vasculopathy, retinopathy
    • interfere with basement membrane function + NO in vasculature leading to abnormal vasculature and collagen production
    • interferes DNA function and repair
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Characteristics of elevation of protein kinase C in DM

A
  • @ renal and vascular cells ==> production of ECM proteins collagen and fibronectin ==> basement membrane thickening
  • @ endothelial cells PKC elevations ==>
    • increased expression of ICAMs
    • increased expression of plasminogen inhibitor activator-1 (PAI-1)
    • increased expression of vascular endothelial growth factor (VEGF)
    • defective production of vasodilating factor NO.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Characteristics of elevation of oxidative carbonyl stress in DM

A
  • Diabetes is associated with increased extracellular and intracellular oxidative burden.
  • ↑ intracellular reactive oxygen species → short term cellular dysfunction + long-term tissue damage.
  • Oxidant injury leads to enzymatic blockade of normal glycolysis leading to shunting of glucose metabolites into the deleterious pathways outlined above.
  • Circulating and intracellular antioxidant levels are decreased in diabetes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Brownlee unifying hypothesis

A
  • glucose usually goes to mitochondria
  • If excess glucose, mitochondria becomes uncoupled, leads to reactive O2 species → retinopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Microvascular complications in DM

A
  • Retinopathy
  • Neuropathy
  • Nephropathy
  • Amputation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Characteristics of diabetic retinopathy

A
  • Periocyte → autoregulation cell of blood flow in retina.
    • Periocytes = neurons and thus love glucose
    • too high or too low causes them to die → rerouting of vascular architecture.
  • Capillary dropout, basement membrane thickening, leakage of intravascular fluids leading to soft and hard exudates → hypoxic state → VEGF → Neovascularization and proliferative retinopathy → blindness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Diabetic retinopathy tx/prevention

A
  • Do annual ophthalmologic examinations, keep tight glycemic control to prevent this
  • May need to intervene with laser therapy, photocoagulation, inject steroids or anti-VEGF (can prevent 80-90% of retinopathy/blindness w/early intervention)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Characteristics of diabetic neuropathy

A
  • Mononeuritis multiplex is unique to diabetes, is an infarction of nerves. Usually sensory only, unless a CN in which case it can be motor and sensory
  • Most common is distal symmetric polyneuropathy → think fingers and toes. Starts as pain and prickling, progresses to numbness. Causes serious troubles in feet including ulcers.
  • Autonomic neuropathy is most dangerous; leads to hypoglycemia unawareness; causes ED, constipation. Strong predictor of premature death.
  • Diabetic amyotrophy (amyotrophy = progressive wasting of muscle tissues)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Characteristics of diabetic nephropathy

A
  • 35% of people with diabetes will get this
  • Long preclinical phase with normal or supranormal GFR
  • Proteinuria is a critical marker
  • Measure microalbumin to assess early changes & treat.
  • Once there is gross proteinuria, rapid degeneration and renal failure ensue
  • Slow progression with ACE-I, tight glycemic control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Macrovascular complications of DM

A
  • CV disease
  • HTN contributes to all microvascular and macrovascular complications of DM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Vascular wall response to DM

A
  1. Abnormal endothelial cell function:
  2. Abnormal vascular smooth muscle cell function
  3. Inflammation and decreased fibrinolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Abnormal endothelial cell fxn in DM

A

a. Abnormal clotting factor production- decreased tPA and increased PAI-1
b. Inflammation due to expression of adhesion molecules (aggregation of platelets and leukocytes)
c. Decreased endothelium dependent vasomotion
d. Increased cytokine and chemokine production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Abnormal vascular smooth muscle cell fxn in DM

A

a. Enhanced vascular smooth muscle (VSM) proliferation and migration
b. Increased production of matrix proteins, cytokines and growth factors
c. Altered contractile function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Abnormal vascular inflammation and decreased fibrinolysis in DM

A

]a.Platelet adhesion and activation

b. Monocyte adhesion and macrophage activation and invasion into sub-intimal space, expression of cytokines and chemokines
c. Foam cell formation and activation of metalloproteinases

17
Q

Tx/prevention of macrovascular complications in DM

A
  • Interventions to decrease cardiovascular risk are even more effective in people w/ DM due to their increased CV burden
  • treatment with b blockers, antihypertensives and lipid lowering agents, have great outcome benefits in this population
  • Aspirin has less of an impact in diabetes, but should be used in high risk subjects and people with diabetes and established CVD.
  • early intensive glycemic control (first 3-10 years of diabetes) in people with diabetes decreases macrovascular events years later.
18
Q

Normal Presentation of hypoglycemia

A
  • Adrenergic sx (mediated by epinephrine/glucagon)
    • Sweating
    • Tremor
    • Tachycardia
    • Anxiety
    • Hunger
  • Neuroglycopenic sx
    • Dizziness
    • Headache
    • Decreased mental activity
    • Clouding of vision
    • Confusion
    • Convulsions
    • Loss of consciousness
19
Q

Characteristics of hypoglycemia unawareness

A
  • loss of adrenergic response to hypoglycemia
  • progress directly to altered mental status
  • often occurs in context of frequent episodes of hypoglycemia